12:55 PM EST, 11/10/2025 (MT Newswires) -- Voyager Therapeutics ( VYGR ) and Transition Bio said Monday that they will collaborate to develop small-molecule therapies targeting the TDP-43 protein in amyotrophic lateral sclerosis and frontotemporal dementia.

The partnership focuses on TDP-43 pathology, which is implicated in over 90% of ALS cases and up to 45% of FTD cases, according to the companies.

Transition Bio has received a single-digit million-dollar upfront payment and may earn up to $500 million in milestone payments, along with high single- to low double-digit royalties on future sales, the companies said.

Under the agreement, Transition Bio will lead discovery and optimization using its condensate platform, while Voyager will have an option to license global development and commercialization rights after a candidate is selected, they said.

Price: 4.23, Change: -0.01, Percent Change: -0.12